康哲药业(00867.HK) 公布,透过附属与湖南麦济生物签订合作协议,据此,集团获得1类新药抗IL-4Rα人源化单抗注射液MG-K10在内地、香港、澳门、台湾及新加坡的共同开发权及独家商业化权利;麦济生物配合商业化活动,并销售、供应产品。合作期限为永久。
MG-K10是一种创新的长效抗IL-4Rα人源化单抗,能同时阻断关键2型炎症因子IL-4和IL-13的信号传导,用于治疗2型炎症性疾病。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-24 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.